New antibiotics in clinical trials for Clostridium difficile.

about

Using bacterial genomes and essential genes for the development of new antibiotics.[Clostridium difficile infection : What is currently available for treatment?]Novel Antimicrobials for the Treatment of Clostridium difficile Infection.

P2860

Q39035296-CB570972-CC01-4189-A20E-9A47E63D7B36 Q40475060-BE5EDD32-854B-40BB-9BEC-642239559B67 Q55405974-9CB6E42E-4178-420C-BA2B-1C414B4319EC

P2860

New antibiotics in clinical trials for Clostridium difficile.

Item

http://www.wikidata.org/entity/Q40615409

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

New antibiotics in clinical trials for Clostridium difficile.

@en

type

Item

label

New antibiotics in clinical trials for Clostridium difficile.

@en

prefLabel

New antibiotics in clinical trials for Clostridium difficile.

@en

P1476

New antibiotics in clinical trials for Clostridium difficile.

@en

P2093

Abigail S Hay

http://www.w3.org/2001/XMLSchema#string

Charles K Babcock

http://www.w3.org/2001/XMLSchema#string

Eric T Slayton

http://www.w3.org/2001/XMLSchema#string

Timothy E Long

http://www.w3.org/2001/XMLSchema#string

P2860

Ridinilazole: a novel therapy for Clostridium difficile infection

The discovery of a novel antibiotic for the treatment of Clostridium difficile infections: a story of an effective academic–industrial partnership

Discovery of LFF571: an investigational agent for Clostridium difficile infection

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

In vivo assessment of SMT19969 in a hamster model of clostridium difficile infection.

Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.

Burden of Clostridium difficile infection in the United States.

Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections.

A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.

Effects of surotomycin on Clostridium difficile viability and toxin production in vitro

P31

scholarly article

P356

10.1080/14787210.2016.1211931

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27410763

http://www.w3.org/2001/XMLSchema#string

P921

antibiotic

Clostridium difficile

New antibiotics in clinical trials for Clostridium difficile.

about

P2860

P2860

New antibiotics in clinical trials for Clostridium difficile.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P921